(From AABB Technical Manual, ed. 14. In press. Courtesy Mark Brecher, MD, editor)
| Factor | Name | In vivo
Half-life |
In
vitro,
4 deg C Half-life |
% of Normal
Needed for Hemostasis |
% In Vivo Recovery | Initial Therapeutic Dose |
| I | Fibrinogen |
|
|
|
|
1 bag cryoprecipitate/7 kg body weight |
| II | Prothrombin |
|
|
|
|
10-20 units//kg body weight |
| V | Labile factor, Proaccelerin |
|
|
|
|
10-20 mL plasma/kg body weight |
| VII | Stable factor, Proconvertin |
|
|
|
|
10-20 units/kg body weight |
| VIII | Anti-hemophilic factor |
|
|
|
|
15-50 units/kg body weight |
| IX | Plasma thromboplastin component, Christmas factor |
|
|
|
|
30-80 units/kg body weight |
| X | Stuart-Prower factor |
|
|
|
|
10-20 units/kg body weight |
| XI | Plasma thromboplastin antecedent (PTA) |
|
|
|
|
10-20 ml plasma/kg body weight |
| XIII | Fibrin-stabilizing factor |
|
|
|
|
500 ml plasma every 3 weeks |
| AT III | Antithrombin III |
|
|
|
|
40-50 IU/kg body weight |
| 1. All dosings are provided as a general guideline for initial therapy, the exact loading dose and maintenance intervals should be individualized for each patient. |
| 2. One unit of coagulation factor is present in each ml of fresh-frozen plasma. |
| 3. DDAVP is the treatment of choice for patients with hemophilia A who are responders. |
| Beutler E, Lichman MA, Coller BS, Kipps TL, eds. Williams' hematology, 5th ed. New York: McGraw-Hill, 1995:1413-58, 1657 |
| Mollison PL, Engelfreit CP, Contreras M. Blood transfusion in clinical medicine. 9th ed. Oxford:Blackwell Scientific Publications, 1993:657-69 |
| Huestis DW, Bove JR, Case J, eds. Practical Blood Transfuson. Fourth Edition. Little Brown and Co. Page 1988:319 |
| Counts RB, Haisch C, Simon TL, Maxwell NG, Heimbach DM, Carrico CJ. Hemostasis in Massivly Transfused Trauma Patients. Annals Surg 190;1979:91-99. |
| Package Inserts |
Posted: Sept. 24, 2001